Expression of leukotriene and its receptors in eosinophilic chronic rhinosinusitis with nasal polyps.
BACKGROUND
Cysteinyl leukotriene (LT) has been proposed in the pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP). This study sought to examine the expression of the LT receptor (LTR) in CRSwNP patients and evaluate the potential role of LTR antagonist (LTRA) in the management of eosinophilic CRSwNP (ECRS) patients.


METHODS
Nasal polyps and uncinate process tissues were collected from 18 ECRS patients, 13 non-eosinophilic CRSwNP (non-ECRS) patients, and 16 control subjects. The messenger RNA (mRNA) and protein expression of LTR (cysteinyl leukotriene receptor 1 [CysLT1R] and cysteinyl leukotriene receptor 2 [CysLT2R]) was examined using quantitative reverse-transcription polymerase chain reaction (qRT-PCR), immunohistochemistry, and Western blot analysis. Moreover, the effects of LTRA and steroids on total nasal symptom scores (TNSS) of uncontrolled ECRS patients were evaluated.


RESULTS
The mRNA and protein expression of CysLT1R and CysLT2R was significantly increased in polyp tissues compared with healthy controls (p < 0.05). Compared with the non-ECRS subset, the ECRS subset showed significantly increased expression of CysLT1R and CysLT2R, as well as leukotriene C4 (LTC4) and leukotriene D4 (LTC4) levels (p < 0.05). Moreover, combined LTRA and steroids significantly decreased TNSS more than steroids alone in uncontrolled ECRS patients (p < 0.01).


CONCLUSIONS
Our findings indicate that LTR was differentially expressed between ECRS and non-ECRS patients, and that LTRA may be used as an additional therapy for ECRS patients.
Allergy Center, Otorhinolaryngology Hospital, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Xingmei
X
Wu
Allergy Center, Otorhinolaryngology Hospital, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Haiyu
H
Hong
Allergy Center, Otorhinolaryngology Hospital, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.|Department of Otolaryngology, the First Affiliated Hospital of Shenzhen University, Shenzhen, China.
Kejun
K
Zuo
Department of Otolaryngology-Head and Neck Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.|Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases, Shanghai, China.
Miaomiao
M
Han
Allergy Center, Otorhinolaryngology Hospital, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Jian
J
Li
Allergy Center, Otorhinolaryngology Hospital, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Weiping
W
Wen
Allergy Center, Otorhinolaryngology Hospital, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Geng
G
Xu
Department of Otolaryngology, the First Affiliated Hospital of Shenzhen University, Shenzhen, China.
Beiping
B
Miao
Allergy Center, Otorhinolaryngology Hospital, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.|Department of Otolaryngology-Head and Neck Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.|Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases, Shanghai, China.
Huabin
H
Li
D000085:Acetates / Q000627:therapeutic use*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D015153:Blotting, Western; D019819:Budesonide / Q000627:therapeutic use; D016022:Case-Control Studies; D002908:Chronic Disease; D003521:Cyclopropanes; D004359:Drug Therapy, Combination; D004804:Eosinophils / Q000378:metabolism; D005260:Female; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D015289:Leukotrienes / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009298:Nasal Polyps / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D011446:Prospective Studies; D011804:Quinolines / Q000627:therapeutic use*; D018077:Receptors, Leukotriene / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012220:Rhinitis / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D012852:Sinusitis / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D013440:Sulfides; D016896:Treatment Outcome
D000085:Acetates; D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D015289:Leukotrienes; D011804:Quinolines; D018077:Receptors, Leukotriene; D013440:Sulfides; D019819:Budesonide; C412375:cysteinyl leukotriene receptor 2; C083169:leukotriene D4 receptor; C093875:montelukast
chronic rhinosinusitis; cysteinyl leukotriene; cytokine; leukotriene receptor antagonist; nasal polyps; steroid